cardiac arrest; cardiopulmonary resuscitation; outcomes Endogenous catecholamine responses in cardiac arrest Adrenaline is released from the adrenal medulla and sympathetic nerve terminals throughout the vascular system. Conditions such as trauma, hypotension, sepsis, and hypoglycaemia increase circulating concentrations of adrenaline and other catecholamines, producing increases in cardiac rate, contractility, and systemic vascular resistance. 7 The highest endogenous concentrations of adrenaline occur in cardiac arrest. 8 Despite these grossly elevated levels, their further augmentation appears to have beneficial haemodynamic effects. 9 Adrenergic receptors have been found in many tissues including the heart, brain, and vascular system. Catecholamines such as adrenaline mediate their actions by stimulating these receptors, and two specific types have been demonstrated. Within these types, further differentiation into al, at2, 13I, (2, and (3 subtypes exist.' 0" Stimulation of a, and a2 receptors causes vasoconstriction of arterial resistance vessels and venous capacitance vessels. In the beating heart, 3,I receptor stimulation increases heart rate and contractility, and in the fibrillating heart may increase the frequency and amplitude of the fibrillating waveform.'2 Stimulation of ( Cerebral function and preservation depend on cerebral perfusion. Since the brain's autoregulatory ability is poor, especially in states of low systemic flow such as are found in cardiac arrest, cerebral perfusion is directly influenced by cardiac output.'5 18 Cerebral perfusion depends upon the gradient between arterial and venous pressures and will also be affected by factors influencing intracranial pressure. Thus, in contrast to the heart, cerebral perfusion occurs during the compression or "systolic" phase of the CPR cycle. Furthermore, the longer the downtime from onset of cardiac arrest to initiation of bystander CPR the poorer the cerebral perfusion. 15 Haemodynamic effects in animal studies Since controlled human studies investigating the mechanisms of action of adrenaline in cardiac arrest are impossible, our knowledge is principally derived from animal models.'0 [19] [20] [21] From these studies it is clear that adrenaline improves the global haemodynamic state in cardiac arrest by increasing systemic vascular resistance (thus increasing aortic diastolic pressure) and altering patterns of regional blood flow, directing blood preferentially to the heart and brain. These actions are dose dependent. With increasing doses, parallel increases can be demonstrated in aortic diastolic pressure, myocardial blood flow and oxygen consumption, and cerebral cortical and brainstem flow. These actions are mirrored by improved rates of outcome parameters such as return of spontaneous circulation and survival.'0
The efficacy of adrenaline may be further affected by its method of administration. It may be introduced intravenously through a peripheral or central vein, by intracardiac injection, or endobronchially, and this may be followed by a method of dispersion such as a bolus of fluid or rapid repeated ventilations. When adrenaline is given exogenously higher arterial concentrations are achieved than can be attained through endogenous production, and when it is given early after the induction of cardiac arrest it has an impact on immediate resuscitability. 22 The extrapolation of animal data to the human clinical situation is, however, fraught with problems. Humans have unique physiological, anatomical, and receptor characteristics, and experimental animals are not usually affected by the principal disease process that leads to adult human cardiac arrest -ischaemic heart disease.
Haemodynamic effects in human studies Adrenaline increases systemic pressures achieved during CPR in a dose dependent fashion, and as a result improves coronary perfusion pressure.'6 23 However, potentially deleterious haemodynamic effects include coronary vasoconstriction and postresuscitation arterial hypertension."
Adrenaline is thought to augment cerebral blood flow by shunting blood from nonessential organs and increasing carotid arterial pressure, with redistribution towards the cerebrum. It may also improve cerebral perfusion by resisting the tendency of the intrathoracic portion of the carotid artery to collapse.24 25 Adrenaline and electrical responses In cardiac arrest, electrical activity may broadly be divided into three groups: ventricular fibrillation/tachycardia (VF/VT), asystole, and electromechanical dissociation (EMD). Without treatment and with the passage of time, the VF waveform decreases in amplitude and frequency. These changes are accompanied by reduction in the probability of successful defibrillation and relate to If improved haemodynamics lead to more favourable outcomes this would be expected to be manifest by a dose-response effect. However, demonstrating this effect has proved difficult. Early anecdotal reports using "high" doses (5-10 mg; HD) of adrenaline suggested beneficial effects on survival and led various groups to investigate the comparative effect of different doses of adrenaline upon outcome. [29] [30] [31] The first prospective, randomised trials compared HD and standard dose (SD) adrenaline and showed an improvement in resuscitation rates, but the number of patients studied was small, and the power of the studies limited. 32 33 Three large prospective randomised North American trials have been published. One (prehospital) study showed a significant improvement in early outcome measures34 and a non-significant trend towards greater discharge rates with high dose adrenaline. However, trends in cerebral performance categories were worse with the higher dose.
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There was no significant difference in the duration of hospital or critical care unit stays. The other two studies did not show any significant improvement in return of spontaneous circulation, resuscitation rates, admission or discharge rates, or neurological outcome with high dose adrenaline. 35 36 A recent French trial confirmed no improvement in return of spontaneous circulation or admission rates and at six months could show no significant difference in survival between HD and SD.37 While neither adverse cardiac nor neurological effects were noted, the number of long term survivors was very small. HUMAN Of the in-hospital studies, none was controlled and none found improvement m discharge rates associated with adrenaline.SSAl Two showed a significantly better outcome following placebo/no drug. 39 41 The data from prehospital studies42,4 comparing adrenaline and placebo are even scantier, but one study showed a trend towards improved survival in those not receiving adrenaline. Although all these studies are prospective, the study with the greatest power was not randomised and investigated a group with a poor prognosis. 44 While the methodologies of most of these studies are not ideal -retrospective or descriptive, with no predetermined control or randomisation -the evidence to date suggests that, if anything, adrenaline has a detrimental effect on outcome.
Conclusion: where do we go from here? Despite the fact that the useost adrenaline in cardiac arrest has been hallowed by time, and that it is the drug of choice in both ERC and AHA guidelines, there is a lack of evidence that it improves outcome. High dose adrenaline provides no additional benefit over standard dose regimens, and pending the results of definitive studies on standard dose v placebo a healthy scepticism is warranted. The first prospective, randomised, double blind controlled trial comparing adrenaline with placebo has recently been published. 45 The study numbers were small and there were no differences in discharge survival. If there are any benefits of adrenaline on overall survival following cardiac arrest they appear to be slight, although it is possible that in certain subgroups of patients the benefit may be more marked. In the meantime the importance of basic life support and prompt defibrillation in the treatment of cardiac arrest cannot be overemphasised.
Summary
In this article we review the evidence supporting the clinical application of adrenaline in cardiopulmonary arrest, and summarise the receptor effects of catecholamines and the basic principles producing perfusion during CPR. Animal and human studies show that in cardiac arrest, adrenaline has positive haemodynamic effects, increasing systemic pressures, myocardial perfusion, and cerebrally directed flow. The problems extrapolating from animal to human data are highlighted.
Studies showing improvements in short term survival outcomes with high dose regimens have not been confirmed by other large prospective randomised trials. There is no evidence that high doses of adrenaline improve survival to hospital discharge. Most studies comparing adrenaline with placebo have been non-randomised and uncontrolled, with major methodological problems. Conclusions are difficult, but if anything adrenaline is associated with poorer outcomes.
